AGENTS AGAINST PNEUMOCYSTIS AND TOXOPLASMA

抗肺孢子虫和弓形虫的药物

• 批准号: 3547647
• 负责人: JAMES R. PIPER
• 金额: $ 60.28万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-07-01 至 1995-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3547647
• 关键词: Betaherpesvirinae; Pneumocystis carinii; Toxoplasma gondii; antiAIDS agent; antiprotozoal agents; antiviral agents; drug design /synthesis /production; drug screening /evaluation; opportunistic infections

This application has been constructed to provide a focused effort designed to produce new drugs to treat patients infected with Pneumocystis carinii, Toxoplasma gondii, or cytomegalovirus infections. The groups include synthetic organic chemists whose goal will be to synthesize new candidate compounds with the aim of identifying agents of greater potency as well as selectivity, biological scientists who will seek to isolate and characterize key enzymes of P. carinii and T. gondii and who will also evaluate the new synthetic compounds for their efficacy against T. gondii both in vitro and in vivo, and virologists who will seek to identify new agents effective against cytomegalovirus in a screening program on selected compounds provided by Du Pont, our industrial partner. Compounds from the synthesis program will also be evaluated against P. carinii in programs at Indiana University sponsored by NIAID.

该应用程序的构建是为了提供专注的努力设计 要生产新药来治疗感染肺炎胸藻的患者， 弓形虫弓形虫或巨细胞病毒感染。 组包括 合成有机化学家的目标是合成新候选人 化合物的目的是确定具有更大效力的药物以及 选择性，将寻求隔离和的生物科学家 表征P. carinii和T. Gondii的关键酶，谁也将 评估新的合成化合物对T. gondii的功效 在体外和体内，以及试图识别新的病毒学家 在选定的筛查程序中有效防止巨细胞病毒的代理 我们的工业合作伙伴杜邦（Du Pont）提供的化合物。 来自 合成计划还将在针对Carinii的P. carinii中进行评估 印第安纳大学由Niaid赞助。